Objectives: The aim of this work is to compare and evaluate different modalities of treatment of enuresis with emphasis on benefits, drawbacks, and successfulness of each modality. Patients and Methods: The present study included 249 patients who presented by nocturnal wetting. The mean age was 9.2 ± 2.8 years. The study included both sexes with a male: female ratio 1: 1. The included patients were classified into 7 groups according to the treatment they received. They were further subclassified into 4 groups according to the type of enuresis. All patients were subjected to detailed history, meticulous examination and investigations to detect patients with exclusion criteria. Each therapeutic modality was given for 2 months and another 2 months was needed for follow up and assessment of successfulness of each modality. Results: Placebo overall total response was 58% while placebo overall total relapse was 33.3%. Motivational counseling overall total response was 83.7% while its overall total relapse was 4.1%. Bladder exercises overall total response was 58.9% while bladder exercises total relapse was 11.9%. Imipramine overall total response was 71.8% while its total relapse was 50%.Oxybutynin total response was 63.1% while the overall total relapse was 62.6%. Diclofenac overall total response was 56.8% while the overall total relapse was 54.2%. DDAVP overall total response was 98.2% while its overall total relapse was 29.8%. Conclusion & Recommendations: DDAVP is considered the drug of choice in treating PMNE patients. Oxybutynin, imipramine, diclofenac, and DDAVP are equally effective in treating PSNE patients. Oxybutynin, diclofenac, and DDAVP almost have the same results in management of patients with secondary nocturnal enuresis. Previous treatment failures or relapses and the price of the drug may guide our choice. Desmopressin and imipramine have good results in patients with familial nocturnal enuresis.